These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18469342)

  • 1. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
    Pearce CL; Van Den Berg DJ; Makridakis N; Reichardt JK; Ross RK; Pike MC; Kolonel LN; Henderson BE
    Hum Mol Genet; 2008 Aug; 17(16):2456-61. PubMed ID: 18469342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
    Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
    Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
    Li J; Coates RJ; Gwinn M; Khoury MJ
    Am J Epidemiol; 2010 Jan; 171(1):1-13. PubMed ID: 19914946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
    Söderström T; Wadelius M; Andersson SO; Johansson JE; Johansson S; Granath F; Rane A
    Pharmacogenetics; 2002 Jun; 12(4):307-12. PubMed ID: 12042668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.
    Li Q; Zhu Y; He J; Wang M; Zhu M; Shi T; Qiu L; Ye D; Wei Q
    Mol Biol Rep; 2013 May; 40(5):3597-608. PubMed ID: 23277398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE; Reichardt JK; Nguyen H; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
    Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
    Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
    Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
    Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
    Mononen N; Ikonen T; Syrjäkoski K; Matikainen M; Schleutker J; Tammela TL; Koivisto PA; Kallioniemi OP
    Br J Cancer; 2001 May; 84(10):1344-7. PubMed ID: 11355945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
    Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
    Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
    Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
    Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer: A meta-analysis based on 20 publications.
    Fang C; Guo ZQ; Chen XY; Liu TZ; Zeng XT; Wang XH
    Medicine (Baltimore); 2017 May; 96(19):e6791. PubMed ID: 28489754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
    Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
    Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.
    Choubey VK; Sankhwar SN; Carlus SJ; Singh AN; Dalela D; Thangaraj K; Rajender S
    Asian Pac J Cancer Prev; 2015; 16(3):1033-6. PubMed ID: 25735326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J
    Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
    Choi SY; Kim HJ; Cheong HS; Myung SC
    Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.